<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="83893">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02013141</url>
  </required_header>
  <id_info>
    <org_study_id>0101</org_study_id>
    <nct_id>NCT02013141</nct_id>
  </id_info>
  <brief_title>Telavancin Pediatric PK Study (Ages &gt;3 Months to 17 Years)</brief_title>
  <official_title>An Open-Label Study of the Pharmacokinetics of a Single Dose of Telavancin in Pediatric Subjects Aged 3 Months to 17 Years</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Theravance Biopharma Antibiotics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Theravance Biopharma Antibiotics, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicenter, open-label, single-dose pharmacokinetic (PK) study. Infants,
      children, and adolescents will receive a single 10 mg/kg dose of telavancin infused
      intravenously (IV) over 60 minutes
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2014</start_date>
  <completion_date type="Anticipated">June 2017</completion_date>
  <primary_completion_date type="Anticipated">June 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetics- AUC (area under curve)</measure>
    <time_frame>24 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics- Cmax</measure>
    <time_frame>24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics- Tmax</measure>
    <time_frame>24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics- t1/2</measure>
    <time_frame>24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics- CLp (plasma clearance)</measure>
    <time_frame>24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AEs (adverse events)</measure>
    <time_frame>24 hours</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Gram-Positive Bacterial Infections</condition>
  <arm_group>
    <arm_group_label>Telavancin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Telavancin 10 mg/kg IV administered over one hour one time.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Telavancin</intervention_name>
    <arm_group_label>Telavancin</arm_group_label>
    <other_name>VIBATIV</other_name>
    <other_name>TD-6424</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject is aged &gt;3 months to 17 years (inclusive) and has a weight within the 3rd to
             97th percentile (inclusive) for age and sex

          -  Subject requires or recently completed systemic antibiotic therapy for the treatment
             or prevention of a known or suspected bacterial infection

        Exclusion Criteria:

          -  Subject has an estimated creatinine clearance &lt;50 mL/min/1.73 m2 (Schwartz equation)

          -  Subject has a history of allergies or hypersensitivities to glycopeptide antibiotics
             (e.g., vancomycin), telavancin, or the formulation excipients

          -  Subject has clinically relevant cardiac abnormality, in the opinion of the
             investigator

          -  Subject was treated with an investigational drug within 30 days or five half-lives,
             whichever is longer, before study entry
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Months</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bibiana Castaneda, MD</last_name>
    <role>Study Director</role>
    <affiliation>Theravance Biopharma Antibiotics, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mia Elliott</last_name>
    <phone>650-808-6000</phone>
    <email>MElliott@theravance.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Brenda Shamlian</last_name>
    <phone>650-808-6000</phone>
    <email>BShamlian@theravance.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Hospitals Case Medical Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Speicher, M.D.</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <lastchanged_date>January 17, 2017</lastchanged_date>
  <firstreceived_date>December 11, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Gram positive bacteria</keyword>
  <keyword>Telavancin</keyword>
  <keyword>VIBATIV</keyword>
  <keyword>Pediatric</keyword>
  <keyword>Pharmacokinetics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Bacterial Infections</mesh_term>
    <mesh_term>Gram-Positive Bacterial Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Telavancin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
